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Equine infectious anemia virus (EIAV), a lentivirus distantly related to HIV-1, encodes regulatory proteins, EIAV Tat (ETat) and Rev
(ERev), from a four-exon mRNA. Exon 3 of the tat/rev mRNA contains a 30-nucleotide purine-rich element (PRE) which binds both ERev
and SF2/ASF, a member of the SR family of RNA splicing factors. To better understand the role of this element in the regulation of EIAV
pre-mRNA splicing, we quantified the effects of mutation or deletion of the PRE on exon 3 splicing in vitro and on alternative splicing in
vivo. We also determined the branch point elements upstream of exons 3 and 4. In vitro splicing of exon 3 to exon 4 was not affected by
mutation of the PRE, and addition of purified SR proteins enhanced splicing independently of the PRE. In vitro splicing of exon 2 to exon 3
was dependent on the PRE; under conditions of excess SR proteins, either the PRE or the 5V splice site of exon 3 was sufficient to activate
splicing. We applied isoform-specific primers in real-time RT-PCR reactions to quantitatively analyze alternative splicing in cells transfected
with rev-minus EIAV provirus constructs. In the context of provirus with wild-type exon 3, greater than 80% of the viral mRNAs were
multiply spliced, and of these, less than 1% excluded exon 3. Deletion of the PRE resulted in a decrease in the relative amount of multiply
spliced mRNA to about 40% of the total and approximately 39% of the viral mRNA excluded exon 3. Ectopic expression of ERev caused a
decrease in the relative amount of multiply spliced mRNA to approximately 50% of the total and increased mRNAs that excluded exon 3 to
about 4%. Over-expression of SF2/ASF in cells transfected with wild-type provirus constructs inhibited splicing but did not significantly alter
exon 3 skipping.
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Introduction 1999; Sun et al., 1993; Tange and Kjems, 2001; Tange et al.,Retrovirus gene expression depends on both alternative
splicing and diverse mechanisms to export intron-containing
mRNAs to the cytoplasm. Alternative splicing is controlled
by essential elements such as splice sites and branch point
sequences (BPS) as well as exonic splicing enhancer (ESE),
exonic splicing suppressor (ESS), and intronic splicing
suppressor (ISS) elements (Amendt et al., 1994, 1995;
Bilodeau et al., 2001; Damgaard et al., 2002; Jacquenet et
al., 2001; Ladd and Cooper, 2002; Schaal and Maniatis,0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2003.12.028
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E-mail address: derse@ncifcrf.gov (D. Derse).2001). RNA transport is regulated by interactions of a cis-
acting RNA element (CTE, constitutive transport element)
with cellular proteins or, in lentiviruses, a Rev-responsive
element (RRE) with the viral Rev protein (Harris and Hope,
2000; Wodrich and Krausslich, 2001). In the lentivirus
equine infectious anemia virus (EIAV), the RRE is embedded
in a 30-nucleotide-long purine-rich element at the 3V end of
exon 3 and has been shown to affect RNA export through
interaction with viral Rev protein (Gontarek and Derse,
1996; Harris et al., 1998; Martarano et al., 1994). EIAV Tat
(ETat) and Rev (ERev) proteins are encoded in a bicistronic
mRNA containing four exons. ETat is encoded in exons 1
and 2; ERev is encoded in exons 3 and 4. It was shown
previously that expression of ERev induced exon 3 skipping
(Martarano et al., 1994). Mutation of the exon 3 purine-rich
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1996). In addition to binding ERev, this purine-rich element
(PRE) was shown to interact with cellular SR proteins and
was proposed to function as an ESE (Belshan et al., 2000;
Chung and Derse, 2001; Gontarek and Derse, 1996). How-
ever, because the earlier methods did not quantify alterna-
tively spliced mRNAs, the extent to which exon 3 inclusion
was dependent on the purine-rich element is unknown.
SR proteins belong to a family of splicing factors con-
taining RNA recognition motifs in the amino-terminal region
and a serine/arginine-rich domain in the carboxyl-terminal
region. SR proteins are essential for both constitutive and
alternative pre-mRNA splicing (Fu, 1995; Graveley, 2000;
Tacke and Manley, 1999). In the early catalytic step of the
splicing reaction, the first nucleotide at the 5V end of an intron
forms a 2V–5V phosphodiester linkage with the adenosine at
the branch site and generates lariat intermediates. The base
pairing between U2 snRNA and the branch point sequence
(BPS) plays an important role in accomplishing this step (Wu
and Manley, 1989; Zhuang and Weiner, 1989). The BPS is
generally located 18–37 nucleotides upstream of the 3V
splice site with the consensus sequence YNYURAY (where
Y is a pyrimidine, N is any nucleotide, and R is a purine) in
which only the branch adenosine is invariant (Reed and
Maniatis, 1985). Deviation from the consensus BPS affects
pre-mRNA splicing efficiency and 3V splice-site selection
(Reed and Maniatis, 1988). The 3V splice site includes the 3V
AG dinucleotide and an adjacent upstream polypyrimidine
tract with which U2AF35 and U2AF65 interact, respectively
(Merendino et al., 1999; Wu et al., 1999; Zamore et al., 1992;
Zorio and Blumenthal, 1999). The sequence of the BPS and
of the polypyrimidine tract determines their recognition by,Fig. 1. A schematic representation of the EIAV pre-mRNA minigenes: pKS-Ex23,
lines represent introns; stippled boxes represent exonic splicing enhancer (ESE) re
represent the polypyrimidine tract. The native intron 3 was shortened in the minig
deleted. RNAs were transcribed in vitro from the T7 promoters at the 5V end of the
in exon 3 is shown at the bottom with the three repeats, matching SF2/ASF cons
(B11/SubT) versions of the purine-rich element are shown below the wild-type eand therefore, interactions with splicing factors, which in
turn contribute to the regulation of alternative splicing
(Garcia-Blanco et al., 1989).
In the following studies we asked how the purine-rich
tract in exon 3 and SR proteins affect the alternative splicing
of exon 3. We first examined the splicing of exon 3 with
upstream exon 2 and downstream exon 4 in simple two-
exon models in vitro. Because the functional significance of
the PRE with respect to alternative splicing of exon 3 has
not been assessed by quantitative means, we applied iso-
form-specific primers in real-time QRT-PCR to quantify
RNA splicing in cells transfected with wild type and mutant
proviruses. We also asked how expression of EIAV Rev
protein or over-expression of cellular SF2/ASF and hnRNP
A1 proteins affects basal and alternative splicing of EIAV
pre-mRNA. In addition, we determined the branch point
elements upstream of exons 3 and 4 that influence splice
acceptor site utilization.Results
In vitro splicing reactions of EIAV pre-mRNA
To understand the regulation of EIAV pre-mRNA alter-
native splicing and the role of the purine-rich element within
exon 3, we constructed minigene plasmids that contained
exons 2 and 3 or exons 3 and 4 (pKS-Ex23 and pKS-Ex34,
respectively). Their corresponding introns and essential cis-
acting sequence elements (5V splice sites, 3V splice sites,
branch point sequences, and polypyrimidine tract regions)
were present as illustrated in Fig. 1. The minigene RNAspKS-Ex34, and pKS-Ex234D5Vsi3. Open boxes represent exons; horizontal
gions; solid circles represent branch point sequences (BPS); hatched boxes
ene constructs. The splice-acceptor site of exon 2 in pKS-Ex234D5Vsi3 was
minigenes as indicated. The nucleotide sequence of the purine-rich element
ensus binding sites, underlined. Sequences for deleted (DESE) or mutated
lement.
H.-J. Liao et al. / Virology 323 (2004) 131–140 133were generated by in vitro transcription using T7 RNA
polymerase. Optimal conditions for in vitro splicing reac-
tions were defined with 3–4 RNA. Splicing activity was
first detected after 1 h of reaction, approached the maximum
at 2 h, and leveled off thereafter (data not shown). Splicing
activity reached a maximum in the presence of 2.0 mM
Mg2+. Splicing products and intermediates were identified
by examining various EIAV RNAs containing differentFig. 2. Influence of the purine-rich element and SR proteins on splicing of two-ex
by denaturing gel electrophoresis and autoradiography. (A) Splicing of exon 3 to ex
3 without the PRE (DESE, lanes 4–6). Splicing reactions were carried out in the p
proteins (SR) as indicated. Splicing products are depicted to the right and molecula
exon 3 with minigene RNA substrates containing wild-type exon 3 (lanes 1–3), e
substitutions in the PRE (B11/SubT). Nuclear extract and SR proteins were present
the 5V splice site of exon 3 was mutated and contained either the wild-type PRE (W
representation of wild type and mutated exon 2–3 RNA substrates used in panelinsertions or deletions in exon 3, intron 3, or exon 4 and
comparing migration patterns of reaction products in dena-
turing gels (data not shown).
SR proteins promote EIAV pre-mRNA splicing in vitro
We first examined the in vitro splicing of EIAV mRNA in
the context of simple, two-exon RNA substrates. SR proteinson EIAV RNA substrates in vitro. In vitro splicing reactions were examined
on 4 with minigene RNAs containing wild-type exon 3 (lanes 1–3) or exon
resence or absence of HeLa nuclear extract (NE) or addition of purified SR
r size standards are shown to the left of the panel. (B) Splicing of exon 2 to
xon 3 without the PRE (DESE, lanes 4–6), or exon 3 containing nucleotide
as indicated. (C) Splicing of exon 2 to exon 3 with RNA substrates in which
T, lanes 1–2) or were deleted of the PRE (DESE, lanes 3–4). (D) Schematic
s B and C.
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to exon 4 (Fig. 2A, lanes 1–3). To determine whether the
purine-rich element in exon 3 is required for this activation
by SR proteins, we examined RNA substrates with a deletion
of the PRE that are designated as DESE RNAs (Fig. 2A,
lanes 4–6). In vitro splicing of wild type and DESE RNAs
was comparable both in the presence or absence of added SR
proteins (Fig. 2A, lanes 3 and 6). These results indicated that
the exon 3 purine-rich element was not essential for SR
protein activation of exon 3 to exon 4 splicing.
We next examined the effects of SR proteins on exon 2 to
exon 3 splicing in vitro with RNA substrates containing a
wild type, deleted (DESE), or mutated (B11/SubT) exon 3
PRE (Fig. 1). In the absence of added SR proteins, deletion
of the PRE caused a modest decrease in the basal level of
splicing of exon 2 to exon 3 (Fig. 2B, lanes 2 and 5), but the
B11/SubT mutation had no effect (lanes 7–9). Addition of
purified SR proteins to splicing reactions activated splicing
on all three substrates to the same extent (Fig. 2B, lanes 3, 6,
and 9), indicating that excess SR proteins enhanced splicing
independently of the PRE. A 5V splice site has been reported
to enhance splicing and affect the binding of U2AF65 to the
upstream 3V splice site of the alternatively spliced exon
(Hoffman and Grabowski, 1992; Kuo et al., 1991). There-
fore, wild type and DESE RNA substrates containing
mutations of the 5V splice site of exon 3 were examined
(Fig. 2C). When the purine-rich element was present,
splicing occurred and was activated by addition of SR
proteins (Fig. 2C, lanes 1 and 2). In contrast, exon 2 to
exon 3 splicing was not detected in the double mutant
(DESE plus 5V splice site mutation), and addition of SRFig. 3. Real-time QRT-PCR analysis of in vitro splicing reactions. (A) Primer p
specifically pre-mRNA, 3/4-spliced mRNA, and 2/4-spliced mRNA, respectively. T
four-nucleotide overhang at the 3V end of the primer that is complementary to the firs
the 3/4 primer. Primer locations relative to introns and exons are shown under the RN
real-time QRT-PCR reactions. Lanes 1–4 show the products from real-time QRT
products using unspliced-specific primers. In vitro splicing reactions were perform
nuclear extract alone (lanes 2 and 6), and with HeLa nuclear extract and SR protei
transcription reactions as controls for carried-over DNA templates (lanes 4 and 8).
below each lane. ND signifies that no signal was detected by the fluorescence recproteins did not activate splicing (Fig. 2C, lanes 3 and 4).
Because the RNA substrates used in panels B and C differed
in the length of their 3V termini (Fig. 2D), we also examined
splicing of RNAs like those used in panel C but which
contained a wild type 5V splice site. These RNAs responded
to SR proteins in a similar way as the RNAs shown in panel
B (data not shown). Thus, either the purine-rich tract or the
5V splice site of exon 3 was required for efficient splicing of
exon 2 to exon 3 in vitro.
Real-time QRT-PCR analysis of pre-mRNA splicing with
isoform-specific primers
PCR primers were designed that would specifically and
differentially amplify unspliced pre-mRNA, spliced mRNA
in which exon 3 was included (2/3/4 mRNA), or spliced
mRNA in which exon 3 was excluded (2/4 mRNA) (Fig.
3A). The unspliced template was selectively amplified by
positioning the 5V primer (USP) within intron 3. The spliced-
isoform-specific primers were designed such that they are
complementary to one exon and have four bases at their 3V
end that are complementary to the adjoining exon. Plasmids
containing provirus, 3/4-spliced cDNA, or 2/4-spliced
cDNA were used to establish standard curves for real-time
QRT-PCR reactions. In addition, the specificity of each
primer pair was determined by testing their ability to
amplify 10 pg of each of the three plasmid DNAs. In every
case, only the cognate plasmid was amplified; for example,
E4 plus 3/4-spliced-isoform-specific primers did not ampli-
fy plasmid DNA encoding unspliced or 2/4-spliced cDNAs
(unpublished observation).airs, USP and E4, 3/4 and E4, and 2/4 and E4, were designed to monitor
he 5V region of the 3/4 primer is complimentary to the 3V end of exon 3 with a
t four nucleotides in exon 4. The 2/4 primer is based on the same principle as
A isoforms that they detect. (B) Gel electrophoresis of the end products from
-PCR reactions using 3/4 spliced-specific primers; lanes 5–8 show the end
ed without HeLa nuclear extract or SR proteins (lanes 1 and 5), with HeLa
ns (lanes 3, 4, 7, and 8). Reverse transcriptase was omitted from the reverse
The threshold cycle (Ct) at which PCR products were first detected is shown
order after 41 cycles of PCR.
Table 2
Quantitative analysis of alternative splicing in cells transfected with EIAV
provirus expression plasmids, p8511 or p8511DESE
Rev SF2 A1 WT DESE
2/4 3/4 USP 2/4 3/4 USP
p8511    0.13 80.6 19.3 39.0 1.35 59.9
p8511 +   4.23 44.7 51.1 38.4 0.97 60.6
p8511  +  0.21 18.0 81.8 8.84 1.66 89.5
p8511 + +  0.36 17.4 82.6 9.01 2.53 87.9
p8511   + 0.31 84.8 15.3 34.8 0.29 64.9
p8511 +  + 5.6 44.0 50.3 42.6 0.46 56.9
Total cellular mRNA was isolated from D17 cells cotransfected with
provirus plasmids in combination with expression plasmids encoding ERev,
SF2/ASF (SF2), or hnRNP A1 (A1), as indicated. RNAs were analyzed by
real-time RT-PCR using 2/4-spliced-specific primers, 3/4-spliced-specific
primers, and unspliced-specific primers for the detection of 2/4-spliced, 3/4-
spliced, and unspliced (USP) mRNAs, respectively. The percentage of each
mRNA isoform, relative to the sum of the three, is shown for each
transfection condition. WT indicates wild-type exon 3 and DESE indicates
deletion of the PRE in exon 3. All PCR reactions were done in triplicate and
standard deviations of at least three determinations were below 20% of the
mean values.
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vitro RNA splicing reactions with the EIAV exon 3–4 RNA
substrate. In vitro splicing reactions were performed as
described above followed by reverse transcription. The
cDNA generated was analyzed for 3/4-spliced molecules
and unspliced RNA molecules by real-time QRT-PCR in
triplicate reactions. No amplification was observed in re-
verse transcriptase-minus reactions after 41 PCR cycles
either by gel electrophoresis (Fig. 3B, lanes 4 and 8) or
by fluorescence recorder. This indicated that the detected
amplicon was indeed from RNA and not from carried-over
template DNA in the RNA preparations. The fact that no
spliced-specific amplicon was detected from splicing reac-
tions without nuclear extract, which would contain only the
input RNA substrate, (Fig. 3B, lane1) confirmed the primer
specificity. Melt curves were also routinely used to assess
specificity of amplification.
To evaluate assay variation, RNA from two independent
in vitro transcription reactions was used in three indepen-
dent splicing reactions followed by three independent re-
verse transcription reactions. Two different reverse
transcriptases were compared, either Omniscript (Qiagen)
or Superscript II RNAseH- Reverse Transcriptase (Invitro-
gen). cDNAs from the three independent reverse transcrip-
tion reactions were then used in six real-time QRT-PCR
assays in which each reaction was run in triplicate. The
results are presented as percentage of 3/4-spliced product
(spliced RNA / spliced RNA + unspliced RNA) in Table 1.
The mean percentage of 3/4-spliced product was 0% with-
out nuclear extract, 15.4% with nuclear extract, and 34.4%
with nuclear extract and SR proteins. The levels of 3/4-
spliced products determined by real-time QRT-PCR were
similar to values obtained by denaturing-polyacrylamide gel
electrophoresis (Fig. 2A) and phospho-image analysis.
Phospho-image analysis gave 12.2% 3/4-spliced product
in reactions with nuclear extract and 30.4% for reactions
containing nuclear extract plus SR proteins.
Quantitative analysis of exon 3 alternative splicing in vivo
We next applied real-time QRT-PCR to quantify the
effects of cis- and trans-acting factors on EIAV alternativeTable 1
Quantitative analysis of EIAV exon 3–4 RNA splicing in vitro
1 2 3 4 5 6 Mean F SD
NE SR
  0.0 0.0 0.0 0.0 0.0 0.0 0.0 F 0.0
+  14.2 15.6 14.5 12.9 16.4 19.1 15.4 F 2.1
+ + 34.1 31.1 28.9 33.7 39.5 38.9 34.4 F 4.2
cDNA derived from in vitro splicing reaction of 3–4 RNA, with or without
HeLa nuclear extract (NE) or purified SR proteins (SR) as indicated, was
quantitatively analyzed by real-time QRT-PCR using 3/4-spliced-specific
primers and-unspliced specific primers. Values shown are the percentage of
3/4-spliced product copy number [i.e. 3/4 spliced  (3/4 spliced +
unspliced)]. Mean values F SD were computed from six independent real-
time QRT-PCR experiments. All reactions were done in triplicate.splicing in vivo. D17 cells were transiently transfected with
rev-minus proviruses or minigene constructs containing
wild type or PRE-deleted versions of exon 3. Real-time
QRT-PCR analysis was performed using the primer pairs
(Fig. 3A) that detect unspliced mRNA, 3/4-spliced mRNA
(exon 3 inclusion), or 2/4-spliced mRNA (exon 3 exclu-
sion). The relative amount of each viral mRNA was
expressed as the percentage of the sum of all three mRNAs
(Table 2). In cells transfected with the wild-type exon 3
provirus construct, p8511, 3/4-spliced mRNA constituted
approximately 81% of the total viral mRNA and 2/4-spliced
mRNA was 0.13%; that is, exon 3 was included in the
majority of multiply spliced mRNAs. In contrast, deletion of
the PRE resulted in reduced levels of viral mRNA splicing
overall and the majority of multiply spliced mRNAs ex-
cluded exon 3; the 3/4-spliced mRNA made up only 1.4%
of the total and the 2/4-spliced mRNA comprised 39% of
the total. A provirus construct containing the B11/SubT
mutation in exon 3 gave results identical to the DESE
mutant (data not shown) Thus, in these provirus constructs,
the purine-rich element was critical for exon 3 inclusion in
multiply spliced mRNAs.
Expression of ERev inhibited splicing of viral mRNA
and increased exon 3 exclusion in the spliced mRNAs; the
2/4-spliced mRNA increased to about 4% and the 3/4-
spliced mRNA decreased to about 45% of the total. With
p8511DESE construct, ERev did not significantly alter the
splicing pattern because the PRE deletion also removed the
Rev response element.
The SR protein SF2/ASF was previously shown to
interact with the purine-rich element in exon 3 in vitro
(Chung and Derse, 2001; Gontarek and Derse, 1996). In
cells transfected with the wild-type provirus, over-expres-
sion of SF2/ASF protein depressed the total yield of spliced
product (Table 2). Expression of the SR protein decreased
Fig. 4. Defining the branch point sequences (BPS) of intron 3 and intron 4.
(A) The strategy for BPS identification is illustrated schematically. EIAV
exon 2–3 pre-mRNA was subjected to in vitro splicing reaction. Lariats
along with other RNA splicing products were recovered and reverse
transcribed (RT) using an antisense-oligonucleotide primer near the 5V
region of intron 2 to generate cDNA (solid lines represent DNA and dashed
lines represent RNA) that encompasses the branch point sequence. The
cDNA was then amplified by polymerase chain reaction (PCR). PCR
products were cloned and sequenced. (B) Consensus BPS, with the
invariable adenosine boxed (Y = pyrimidine; N = any base; R = purine), is
shown for comparison to the nucleotide sequences determined for EIAV
branch point elements. The BPS of intron 2 and intron 3 are underlined. The
branch point adenosine is indicated by an arrowhead. Polypyrimidine tract
sequences, located between the branch point and the 3V splice site, are
displayed with purines shown in lower case letters.
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the low level of 2/4 splicing (exon 3 skipping) of the WT
mRNA. In contrast, on the DESE template that lacks the
purine-rich target of the SR protein, ectopic expression of
SF2/ASF protein decreased the level of the 2/4-spliced
product but had little effect on the level of 3/4 splicing.
The cellular protein hnRNP A1, an antagonist of SF2/ASF
(Bilodeau et al., 2001; Tange et al., 2001), had no effect on
the splicing of the wild type or the DESE proviruses.
Determination of introns 2 and 3 branch point sequences
Although several important cis-acting elements in EIAV
are known, the branch point sequences (BPS) have not yet
been defined. Because BPS and the flanking polypyrimidine
tract are likely to be important for alternative splicing, we
aimed to identify them using a RT-PCR approach. To this
end, in vitro splicing of RNAs transcribed from pKS-Ex23
and pKS-Ex34 were carried out as described above. The
splicing products were then reverse-transcribed utilizing the
ability of Superscript II Reverse Transcriptase (Invitrogen)
to read through the 2V–5V phosphodiester linkage at the
lariat branch site (Vogel et al., 1997; Zheng and Baker,
2000). As illustrated in Fig. 4A, an antisense primer
complementary to the 5V end of the intron was used for
reverse transcription, followed by PCR amplification with a
pair of primers that flank the BPS. Amplified products were
cloned and sequenced.
Of the intron 2 BPS cDNA clones sequenced, two
contained the sequence 5V-GTTTCTA-3V and three were
5V-GTTTCAA-3V; the provirus sequence of this region is
5V-GTTTCAACCTT-3V (italic letters represent the best match
to the consensus BPS) (Fig. 4B). It has been reported that
although MLV reverse transcriptase was able to read
through the 2V–5V phosphodiester bond at the branch site,
the enzyme tends to insert a T residue for the A at the branch
point (Vogel et al., 1997; Zheng and Baker, 2000). The two
BPS clones with 5V-GTTTCT-3V would be in agreement with
these observations, although the three BPS clones with 5V-
GTTTCA-3V would suggest that the A residue at the branch
site had not been replaced by a T. Currently, there is not
enough published data on the fidelity of reverse transcrip-
tase with 2V–5V phosphodiester linkage to resolve this issue.
Thus, the EIAV intron 2 BPS, 5V-UUUCAAC-3V, is the best
match to the consensus (YNYURAY). The intron 2 branch
point adenosine is 24 nucleotides from the 3V splice site, is
interspersed with 11 purines, and hence, lacks a well-
defined polypyrimidine tract (Fig. 4B).
A similar approach indicated that two distinct BPS
elements were present in intron 3 (Fig. 4B). Both BPS
elements, 5V-UAUUUAU-3V and 5V-UGCUU2V–5VU-3V (the
branch site adenosine is shown in bold type), have a six of
seven nucleotide match to the consensus branch point
sequence. The identification of two BPS for intron 3 is
consistent with the observation of multiple lariat signals
from intron 3 on denaturing polyacrylamide gels (Fig. 2A).Multiple BPS elements, though unconventional, have pre-
viously been reported in SV40; selection of BPS governs
the SV40 pre-mRNA alternative splicing and therefore the
expression of large T and small t antigens (Noble et al.,
1988). Presently, the functional significance of multiple BPS
in EIAV mRNA is not known. Between the BPS and the 3V
splice site in intron 3 is a stretch of 22 and 26 pyrimidines
interrupted by 5 and 6 purines, respectively (Fig. 4B).Discussion
The purine-rich element (PRE) in exon 3 RNA contains
three tandemly repeated sequence elements (AAAGAA-
GAA) that match the consensus SF2/ASF binding site.
RNA substrates containing the PRE region were previously
shown to bind SF2/ASF and recombinant ERev proteins in
vitro (Chung and Derse, 2001; Gontarek and Derse, 1996).
It was reported that in vitro splicing of exon 2 to exon 3 was
diminished when the 3V end of exon 3 (including the 5V
splice site and PRE) was deleted or when point mutations
were introduced into the PRE (Belshan et al., 2000). Our in
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splice site and PRE of exon 3 abolished exon 2 to exon 3
splicing, consistent with the earlier exon 3 deletion analyses
(Belshan et al., 2000). However, in our hands, either the 5V
splice site or the PRE was sufficient to enhance splicing,
which differs from the previous report that showed mutation
of the PRE alone significantly decreased splicing. The
ability of a 5V splice site to enhance splicing by recruiting
U2AF65 to the upstream 3V splice site of an alternatively
spliced exon has been demonstrated previously (Kuo et al.,
1991; Hoffman and Grabowski, 1992). The discordance
between our results and those of Belshan et al. (2000) most
likely reflects differences in the RNA substrates or compo-
sition of nuclear extracts used in the two studies. In spite of
these differences, the experiments presented here and before
indicate that the PRE acts as an exonic splicing enhancer
element for exon 2 to exon 3 splicing in vitro.
Although we have previously shown that mutation of the
PRE caused exon 3 skipping in cells transfected with EIAV
proviruses (Gontarek and Derse, 1996), the extent to which
exon 3 inclusion was dependent on the PRE was not
determined. Moreover, the effects of viral and cellular
trans-acting factors on viral mRNA splicing have not been
examined by quantitative methods. To monitor the levels of
individual viral mRNA species produced in transfected
cells, we developed a real-time RT-PCR method to address
this issue. This quantitative method was essential for deter-
mining the biological relevance of PRE function, both as an
ESE and as an RRE. In cells transfected with the rev-minus
provirus clone, p8511, approximately 80% of the viral
mRNAs were spliced to include exon 3 and only 0.13%
skipped exon 3. Deletion of the PRE resulted in a reduction
in the overall levels of multiply spliced viral mRNAs and
increased levels of unspliced mRNA. At the same time,
levels of mRNAs that included exon 3 decreased to about
1% of the total and mRNAs that excluded exon 3 increased
to approximately 40% of the total. Thus, the PRE acts as an
ESE in vivo, having a strong enhancing effect on the
inclusion of exon 3 in multiply spliced mRNA.
In so far as sequence comparisons of the cis-acting
elements that control pre-mRNA splicing can predict splic-
ing efficiency, the 5V splice site and branch point sequences
of exon 3 did not reveal a striking deviation from consensus
sequences. The 5V splice site of exon 3 (G/GUAUGUUU)
had a two-nucleotide mismatch and the branch point had a
single mismatch compared to consensus elements. Thus,
although some alternatively spliced exons have suboptimal
splice site or branch point sequences, this is not the case
with exon 3 of EIAV. On the other hand, the sequence of the
polypyrimidine tract in intron 2 may be suboptimal due to
its high purine content, and may thus contribute to the
regulation of exon 3 inclusion.
In addition to acting as an ESE, the exon 3 PRE also
contains the Rev-responsive element (RRE) which is essen-
tial for the nuclear export of unspliced and partially spliced
viral RNAs (Gontarek and Derse, 1996; Harris et al., 1998;Martarano et al., 1994). Recombinant ERev protein was
shown to bind RNA containing the PRE in vitro (Belshan et
al., 2000; Chung and Derse, 2001; Gontarek and Derse,
1996) and to inhibit in vitro splicing of exon 2 to exon 3
(Belshan et al., 2000). ERev expression was previously
shown to induce exon 3 skipping in cells transfected with
the rev-minus provirus (Gontarek and Derse, 1996; Martar-
ano et al., 1994), but the magnitude of this effect was not
determined. Quantitative analyses presented here indicated
that ectopic expression of ERev caused an approximately 2-
fold increase in the level of unspliced mRNA accompanied
by a 2-fold decrease in spliced mRNA that included exon 3
and an increase in mRNA that excluded exon 3–4% of the
total. It was previously suggested that ERev might nega-
tively autoregulate its own expression because it is encoded
by exons 3 and 4 of multiply spliced mRNA and induces
exon 3 exclusion. The 2-fold decrease in mRNA that
includes exon 3 does not support this conjecture. The more
likely function of ERev with respect to viral mRNA splicing
is to induce a shift from production of multiply spliced
mRNAs to unspliced and singly spliced mRNAs that encode
viral structural proteins.
Because both ERev and SF2/ASF bind to the PRE, two
models were proposed to explain the mechanism of ERev-
induced exon skipping (Gontarek and Derse, 1996). The
first model suggested that the binding of ERev and SF2/
ASF to the PRE is competitive, although the second model
suggested that ERev and SF2/ASF bind to the PRE
simultaneously and ERev inhibits a later step in the
assembly or activity of the spliceosome. The second model
is supported by the previous observation that SF2/ASF and
ERev did not compete for binding to PRE RNA in vitro
(Chung and Derse, 2001). Conversely, transient transfection
experiments showing a decrease in the activity of a Rev-
responsive reporter plasmid in response to SF2/ASF over-
expression was interpreted to support the first model
(Belshan et al., 2000). We attempted to test these models
by transfecting cells with p8511 in combination with ERev
plus SF2/ASF. However, we observed that over-expression
of SF2/ASF alone inhibited EIAV pre-mRNA splicing but
did not affect exon 3 inclusion. This effect was also seen
with p8511DESE, indicating that the effect was indepen-
dent of the ESE in exon 3 and likely due to a squelching
effect; that is, high levels of SF2/ASF sequester other
essential splicing factors in complexes not associated with
pre-mRNA. This inhibitory effect was dominant over the
effects of ERev, thus preventing a test of the proposed
models and providing a cautionary note to interpretations of
this type of experiment.
The RNA binding protein hnRNP A1 has been shown to
act as a negative regulator of splicing in other retroviruses
by binding to intronic or exonic splicing silencers (Blanch-
ette and Chabot, 1999; Burd and Dreyfuss, 1994; Caputi et
al., 1999; Del Gatto-Konczak et al., 1999). Alternative
splicing of the HIV-1 tat mRNA, for example, is controlled
by opposing effects of silencer elements that interact with
H.-J. Liao et al. / Virology 323 (2004) 131–140138hnRNP A1 and enhancer elements that interact with SR
proteins (Bilodeau et al., 2001; Tange et al., 2001). Over-
expression of hnRNP A1 had a negligible effect on alterna-
tive splicing of either wild type or DESE EIAV pre-mRNA
in our cotransfection experiments, indicating that the mech-
anism of alternative splicing for EIAV differs from HIV-1.Materials and methods
Plasmids
The rev-minus EIAV provirus clone, p8511, and the
EIAV exon 1-2-3-4 cDNA clone, pK9 have been described
(Stephens et al., 1990). The pKS-24 cDNA plasmid was
constructed by cloning the RT-PCR product derived from
EIAV provirus-transfected cells as previously described
(Martarano et al., 1994). The plasmid pKS-Ex23 was
constructed by subcloning a PCR product amplified from
the provirus clone (p8511) into bluescript pKS-II and
contains exon 2– intron 2–exon 3 (provirus positions
5082–5780). The plasmid pKS-Ex34 contains EIAV provi-
rus sequences from positions 5336–5557 (exon 3) joined to
positions 7164–7340 (intron 3 and exon 4). Plasmids
designated as DESE have a replacement of the purine-rich
region in exon 3 between positions 5474 and 5525 with the
sequence TATGATCAGATCTG. The ERev expression
plasmid, pRS-ERev-P32G, was derived by site-directed
mutagenesis of pRS-ERev (Martarano et al., 1994) with
nucleotide sequences changed from ATAGATCCT (Ile-Asp-
Pro) to ATTGACGGC (Ile-Asp-Gly). pRS-ERev-P32G dis-
played functional activities identical to wild-type ERev, but
the mutations in ERev-P32G prevent it from being ampli-
fied by the 3/4-spliced-specific PCR primers (Liao and
Derse, unpublished observation). The plasmids pCG-SF2
and pCG-hnRNP A1 were obtained from Javier Caceres
(Caceres et al., 1994).
In vitro RNA synthesis and in vitro splicing
(32P)-labeled RNA substrates for in vitro splicing were
prepared from XhoI linearized DNA templates by in vitro
run-off transcription using Ambion mMESSAGE mMA-
CHINE with T7 RNA polymerase according to the manu-
facturer’s instructions. For exon 2–3 RNAs with mutated
exon 3 5V splice sites, DNA templates for in vitro transcrip-
tion were derived by PCR amplification. PCR reactions
were performed using plasmids pKS-Ex23 and pKS-Ex23D-
ESE as templates with forward primer (5V GGTAATAC-
GACTCACTATAGGGCGAATTGGCTGTGTTTCCTG-3V)
in exon 2 containing a T7 promoter sequence at its 5V-end
and reverse primers containing either an intact exon 3 5V
splice site sequence (5V-markusCATAACAGAAACAT-
ACCTATTTTCCACC-3V) or a mutated sequence (5V-CAT-
AACAGAAACATTAGCATTTTCCACC-3V). HeLa cell
nuclear extract preparation and in vitro splicing reactionswere carried out as described by Mayeda and Krainer
(1999a, 1999b) unless indicated otherwise. Typically, in
vitro splicing reactions were incubated at 30 jC for 2 h in
the presence of 0.5 mM ATP, 20 mM creatine phosphate,
3.2 mM MgCl2, 20 mM Hepes–KOH (pH 7.3), 2.6% PVA,
and 40 units of RNAsin containing 40% nuclear extract with
or without the addition of purified HeLa SR proteins (40 Ag/
ml final concentration). SR proteins were purified from
HeLa cells according to Zahler et al. (1992). Splicing
reaction products were analyzed by electrophoresis on 6%
polyacrylamide/7M urea gels or by real-time QRT-PCR
(described below).
Transfections and RNA purification
Canine D17 cells were transfected with EIAV provirus
clones in combination with ERev, SF2, or hnRNP A1
expression plasmids as previously described (Mayeda and
Krainer, 1999a, 1999b). Total cellular mRNA was prepared
48 h after transfection using Qiagen RNeasy and oligotex
purification methods according to the manufacturer’s pro-
tocols. RNA was converted to cDNA as previously de-
scribed (Mayeda and Krainer, 1999a, 1999b).
Branch point sequence mapping
Splicing products from standard in vitro splicing reac-
tions were reverse transcribed in 20-Al reactions containing
1 AM primer (021oHJL: 5V-TGCGATGCTGACCATGT-
TAC-3V or 022oHJL: 5V-CCCTTTACCAATAATCCCAT-3V
for intron 2; 012oHJL: 5V-CGCCACCAACCCTATATAAT-
3V for intron 3), 0.5 mM dNTPs, 20 mM Tris–HCl (pH 8.4),
50 mM KCl, 5 mM MgCl2, 10 mM DTT, 2 U/Al RNAsin,
and 2.5 U/Al Superscript II RNAseH- reverse transcriptase
(Invitrogen). Reactions were carried out according to man-
ufacturerVs instructions. Intron 2 branch-site primers
021oHJL or 022oHJL with primer 020oHJL (5V-
CAGAAAAATCTAAGTGTGAGG-3V) and intron 3
branch-site primers 005CoHJL (5V-GAGTCCTTCATAC-
CACCAA-3V) with 010oHJL (5V-AAGTCTTCTTGCACA-
GATAG-3V) and cDNA of the corresponding pre-mRNA
splicing products were amplified by PCR using HotStarTaq
Master Mix. Multiple clones of PCR products were then
sequenced to map the branch points.
Real-time QRT-PCR
Gene-specific primer (004oHJL 5V-CCAGGTGTC-
TTCTCGC-3V) was used for reverse transcriptions using
Qiagen Ominiscript or SuperScript II RNAseH- reverse
transcriptase following manufacturer’s instructions. cDNA
products were purified by QIAquick PCR purification
column. The 2/4-spliced-specific forward primer (2/4: 5V-
AAGACAACCTCAATATTTGTTATCAGATCC-3V), 3/4-
spliced-specific forward primer (3/4: 5V-GACTGGTG-
GAAAATAGATCC-3V), and unspliced-specific forward
H.-J. Liao et al. / Virology 323 (2004) 131–140 139primer (USP: 5V-TAGTGATGTTTTTGCTTATTTAT-3V)
were used with a common reverse primer (E4: 5V-
ATTTTTTCTTCAGGTAACGAC-3V) in PCR reactions to
amplify exon2/4-spliced product, exon3/4-spliced product,
and an amplicon encompassing intron 3 and exon 4,
respectively. Real-time QRT-PCR was performed using PE
Biosystems SYBR Green PCR Kit, RNAse-free dH2O and
TE were from Ambion, amplification was detected using
Bio-Rad iCycler iQ Multi-Color Real Time PCR Detection
System. Reactions (25 Al) contained 10 nM 6-carboxy-
fluorescein (FAM), 3.0 mM MgCl2 (2.0 mM for 2/4-
spliced-specific primer pairs), 0.3 AM each of the forward
and reverse primers, 5 U/Al of AmpliTaq Gold, 1 U/Al of
AmpErase UNG, 1 SYBR Green PCR buffer (PE), and
1 dNTP blend with dUTP (PE). Reactions were carried
out at 50 jC for 3 min, 95 jC for 10 min, with 41 cycles of
95 jC for 15 s and 60 jC for 60 s. Melt curves were
performed for all reactions to monitor the quality of ampli-
cons and reactions. Calibration curves were derived by
running 10-fold dilutions of each specific cDNA plasmid
over the range of 2.5  100 to 2.5  107 copies. The cDNA
samples were run at several dilutions. Each assay included
duplicate wells for each dilution of calibration plasmids,
triplicate wells for each sample cDNA, and controls which
included nonspecific plasmid DNA, buffer, or water, all in
duplicate. The threshold cycle values (Ct) were used to plot
the calibration curve. Standard curve data were graphed
using Microsoft EXCEL 2000, which derived the equation
for the line, and calculated the coefficient of variation (CV).
All standard curves had a CV of at least 0.95. The copy
number of a particular cDNA in a sample was calculated
from its measured Ct value with respect to the calibration
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